Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

Area of Science:

• Hepatology and Viral Gastroenterology
• Pharmacological Treatment of Hepatitis C
• Evidence-Based Medicine and Clinical Trials

Background:

• Standard treatment for chronic hepatitis C involves pegylated interferon (peginterferon) and ribavirin.
• The comparative efficacy and safety of peginterferon alpha-2a versus peginterferon alpha-2b remain unclear.

Purpose of the Study:

• To systematically compare the benefits and harms of peginterferon alpha-2a against peginterferon alpha-2b.
• Evaluation based on head-to-head randomized clinical trials in patients with chronic hepatitis C.

Main Methods:

• Comprehensive literature search across multiple databases (Cochrane, MEDLINE, EMBASE, etc.) up to October 2013.
• Inclusion of randomized clinical trials comparing peginterferon alpha-2a and alpha-2b, with or without ribavirin.
• Meta-analysis using fixed-effect and random-effects models, assessing risk of bias and using trial sequential analyses.

Main Results:

• Seventeen trials involving 5847 patients were included; all had a high risk of bias.
• Peginterferon alpha-2a showed a significantly higher sustained virological response (SVR) rate (51%) compared to alpha-2b (43%) (moderate quality evidence).
• No clear difference was found in treatment discontinuation due to adverse events; data on mortality, morbidity, and quality of life were insufficient.

Conclusions:

• Moderate quality evidence suggests peginterferon alpha-2a may lead to higher SVR rates than peginterferon alpha-2b.
• Significant limitations exist due to the high risk of bias in included studies and lack of data on patient-important outcomes.
• Clinical consequences and definitive conclusions on the comparative effectiveness and safety of the two peginterferons cannot be drawn.